Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cetuximab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 346 for your search:
Start Over
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
Phase: Phase IV
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: DERMATUX, NCT01315990
Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer
Phase: Phase III, Phase II
Type: Health services research, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000558804, WCTU-SCOPE-1, EU-20739, EUDRACT-2006-002241-37, ISRCTN47718479, CTA-17853/0202/001-0001, NCT00509561
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066954, ECOG-E5397, E5397, NCT00003809
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA225-006, NCT00063141
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA225-014, NCT00061815
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCI-2009-00639, N0147, U10CA025224, CDR0000355132, NCCTG-N0147, ECOG-N0147, NCT00079274
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13423, I4E-MC-JXBC, CP02-0452, NCT00095199
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA225-099, NCT00112294
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 74
Sponsor: Other
Protocol IDs: Nordic VII, EudraCT no.: 2005-000117-34, NCT00145314
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 62202-046, NCT00148798
Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CAIRO2, NCT00208546
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 62202-013, NCT00154102
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 74
Sponsor: Other
Protocol IDs: CDR0000453839, FFCD-PETACC-8, EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CALGB 80405, U10CA037447, CDR0000455161, NCI-2009-00434, CALGB-C80405, C80405, SWOG-C80405, NCT00265850
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-041, NCT00252564
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 0522, CDR0000458049, NCI-2009-00729, NCT00265941
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000492254, NCCTG-N05C4, N05C4, NCT00362986
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: FIRE-3, NCT00433927
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 74
Sponsor: NCI, Other
Protocol IDs: RTOG 0436, CDR0000538085, NCT00655876
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 0617, CDR0000564240, NCCTG-N0628, CALGB-30609, NCI-2013-01762, NCT00533949
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CO20, CAN-NCIC-CO20, CAN-NCIC-CA182009, CDR0000590316, NCT00640471
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMR 200048-052, 2007-004219-75, NCT00678535
Start Over